Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I believe it’s the strength of the FAP tech. Certain POINT are sat at the table. This is why it’s more important than doxorubicin. More important aspect than many think. If, for whatever reason AVA takes longer to get through the clinic, this is a major ‘fall back’.
Again why this P1 data is vitally import at to Avacta’s future.
The above links by gmcc definitely point in this direction....
Was any more info on this given at the in person AGM? I had assumed that this referred to a new way to use the radiotracer (used in PET scans) that was based on the same basic principle as Precision, i.e., a radiotracer with a linker that makes it unable to enter cells until it is cleaved by FAP in the tumour microenvironment.
PET scans are amazing, but they can cause severe damage around the body, including an increased rate of future cancer. So if Avacta could use Precision to develop a safe(r) type of PET scan, that would be revolutionary.
In some ways, this is similar to the treatment with radionucleids by Point.
gmcc....'Note " Q1 2023 •AVA6000 FAPi PET Imaging Data " mentioned in business update slides .'
They do say data not scanner, so although they might be working on developing a PET scanner, the above reference appears to refer to when they expect to have all the FAPi PET images for all the patients up to that point in the P1 trials, which suggests they will have been scanning patients as well as taking bloods, urine and biopsies. These scans could also be huge if they clearly show not only tumour reduction but also no further tumour development within far reduced timescales.
This gives an idea of the images an FAPi PeT can produce.
https://www.frontiersin.org/files/Articles/854658/fonc-12-854658-HTML/image_m/fonc-12-854658-g001.jpg
How does it work?
Is there fapi pet imaging machine avacta need to buy?
It's almost as if they know FAPa activation works and are now building infrastructure to optimize the patient selection to deliver the AVA6k solution......
Interesting... Now why would Avacta be spending in this area if AVA6K was not working!!!
@gmcc, no worries!
Important thing is this is a significant investment by Avacta and demonstrates great confidence in AVA6000 and the pre|CISION platform.
GLA
Sorry LLP our posts crossed - ditto !
Thanks HighlyGeared for the clarification . That Avacta plan to use PET imaging is a good thing . Think Point Biopharma use this type of technology so opportunity for possible information exchange .
"FAP positivity based on FAP targeted PET imaging has been demonstrated in most common solid tumors7
"https://assets.website-files.com/61449a484d74b2708533bace/62acce17ec10b923b1034095_POINT%20Poster%20PNT6555%20-%20SNMMI%20June%202022.pdf
https://assets.website-files.com/61449a484d74b2708533bace/6255e880945d36a2d0aa668a_POINT%20Biopharma%20PNT6555%20AACR%202022%20Poster.pdf
Point BioPharma using PET Scan imaging …
https://assets.website-files.com/61449a484d74b2708533bace/62858f61bf802b380aeadfcb_POINT%20Biopharma%20Investor%20Presentation%20(May%202022).pdf
Page 6 shows the concept with PSMA (not FAP) for prostate cancer.
GLA
gmcc.
Just to confirm that AS specifically stated during his presentation that they are working on developing a PET imaging system as a research tool in order to check on FAP. This new imaging system has the potential to be very valuable, according to AS.
Great find
Lots of ground breaking work going on in the back ground !
Note " Q1 2023 •AVA6000 FAPi PET Imaging Data " mentioned in business update slides .
Another hint that AVA6000 clinical trial might indeed be progressing ahead .
Before @ beinthelead gets overexcited appreciate not fact & maybe different technology to PET Imaging ,
However Interesting ( AVA6000 The Royal Marsden Principal Investigator: Professor Udai Banerji ) recent article on similar topic liked by Avacta CSO .
---------------------------
"Fiona McLaughlin likes this
The Institute of Cancer Research
The Institute of Cancer Research
41,184 followers
3w • 3 weeks ago
Follow
We are using our understanding of the biology of tumours, alongside cutting-edge laboratory models and artificial intelligence (AI) tools, to discover the best new therapy combinations for cancer patients.
Our scientists have created a prototype test that can predict which drug combinations are likely to work for cancer patients in as little as 24 to 48 hours. The pioneering technique uses AI to analyse large-scale protein data from tumour samples and is able to predict patients' response to drugs more accurately than is currently possible.
Find out more about our work in discovering innovative combinations of therapies: https://lnkd.in/eucd76Vy
https://www.linkedin.com/in/fmclaughlin/recent-activity/